Ask the joint clinical assessments.
Answers come from the published reports, factual accuracy annexes and HTACG guidance. Every claim links to the page it comes from, with the passage highlighted. When the documents do not hold the answer, it says so.
Every PICO, at a glance.
Hover a tile for its comparator, select it for the full record and the page it comes from.
| PICO | Comparator | Evidence | Status | Assessors | Source |
|---|
The reports do not say which Member State asked for which PICO. How populations are split, such as the 3- and 6-month treatment-free intervals for tarlatamab, is the closest public signal.
Outcomes and subgroups in each scope
What the assessment scope asked the developer to report. Page links open the scope table with the rows marked.
How each analysis was judged.
Seventeen analyses across the four assessments, with the objections the assessors raised. Where an analysis rests on a randomised trial, its card also shows how certain the trial results are: risk of bias by outcome, patient-reported outcomes, safety, statistics and subgroups. Choose an objection to see where it recurs.
Evidence gaps.
Each assessment scope asks a set of questions: which comparators, in which populations, on which outcomes. This view lists every question the JCA report leaves without a usable result, and what that leaves for national HTA bodies. Expand an entry to trace it from the scope, through the dossier, to the assessors' own words.
Other requests during the assessment
Requests the assessors sent the developer that did not end in a gap: what was asked, what came back and what the assessors made of it. Requests that did end in a gap are in that gap's trace above.
From EU authorisation to national HTA.
Where each medicine stands
The EU and national steps for each medicine, from EMA authorisation through the JCA to G-BA and HAS. Select a medicine to see its timeline; hover a bar or point for dates, and select a JCA point to open the procedure table in the report.
Indication cross-check
Each JCA report records both the indication the developer submitted to EMA, which the scope was built on, and the final therapeutic indication (section 2.2.1, characteristics of the medicinal product). Changed words are marked. The EPAR is the authoritative source for the authorised wording.
National follow-up
What Germany's G-BA and France's HAS have done since each JCA. A pulsing dot means a procedure is still running.
| Assessment | G-BA · Germany | HAS · France |
|---|
Every JCA, running, stopped or published.
From EMA validation to today
Why JCAs were discontinued
Ongoing assessments
The indication is the Commission's summary of what the developer claimed. Assessor and co-assessor are the HTA bodies the JCA subgroup appointed.
| Medicine | Type | EMA validation | Assessor · co-assessor |
|---|
Who assesses
Appointments across all JCAs in the tracker, counting each HTA body once per role.